70 completed, 15 recruiting, 13 withdrawn, 11 terminated. 129 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 129 | Completed 70, Recruiting 15, Withdrawn 13, Terminated 11, Unknown 7, Not yet recruiting 6, Active not recruiting 4, Enrolling by invitation 2, Suspended 1 |
Follow Narcotic-Related Disorders: new trials by email Literature Review of Narcotic-Related Disorders trials Research Report on Narcotic-Related Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Examining Analgesic Synergy and Efficacy in Trauma Care Buprenorphine, Oxycodone - Opioid Use Disorder | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 282 | 2027-03-01 | 2026-10-28 |
| Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic Buprenorphine - Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 60 | 2026-09-23 | 2026-10-09 |
| A Bundled Intervention to End Opioid Overdoses Bundled intervention (Experimental), control group, Buprenorphine (Experimental) - Opioid Use Disorder, Opioid Overdose | Phase 4 | Recruiting | University of Alabama at Birmingham | 160 | 2026-09-07 | 2026-10-02 |
| NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection - HIV Infections, Opioid Use Disorder | Phase 4 | Not yet recruiting | Duke University | 450 | 2026-09-01 | 2026-08-26 |
| Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets) - Opioid Use Disorder, Fentanyl | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-06-01 | 2026-03-13 |
| Methadone Rapid Restart Methadone - Opioid Use Disorder | Phase 4 | Not yet recruiting | Pouya Azar | 25 | 2026-05-01 | 2026-04-22 |
| Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL) - Opioid Use Disorder | Phase 4 | Recruiting | Pouya Azar | 12 | 2026-04-29 | 2026-05-01 |
| Injectable Buprenorphine in Prison: A Preference Trial Brixadi (Injectable Buprenorphine), Sublocade - Opioid Use Disorder, Incarceration | Phase 4 | Recruiting | Lifespan | 60 | 2026-02-18 | 2026-05-15 |
| Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine Morphine, Bupivacaine, Fentanyl - Opioid Use Disorder | Phase 4 | Withdrawn | University of North Carolina, Chapel Hill | 2026-02-01 | 2026-03-09 | |
| Better Options for Chronic Cancer Pain Multimodal pain care, Medication optimization, Buprenorphine rotation - Chronic Pain, Cancer Survivor | Phase 4 | Recruiting | VA Office of Research and Development | 294 | 2025-10-07 | 2026-05-11 |
| Assessing Optimal XRB Initiation Points in Jail Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB) - Opioid Use Disorder | Phase 4 | Recruiting | NYU Langone Health | 50 | 2025-06-02 | 2026-08-07 |
| Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery Buprenorphine Transdermal System, Placebo Patch - Pain, Postoperative, Ankle Fracture Surgery | Phase 4 | Recruiting | Jenna-Leigh Wilson | 100 | 2025-04-21 | 2026-04-06 |
| Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets - Opioid-Induced Constipation, Pain Cancer | Phase 4 | Not yet recruiting | Henan Cancer Hospital | 203 | 2025-04-01 | 2025-03-27 |
| A Bundled Intervention a bundled intervention, including peer support specialist, buprenorphine, physician care, and telehealth - Opioid Use Disorder, Opioid Overdose | Phase 4 | Completed | University of Alabama at Birmingham | 30 | 2025-02-13 | 2026-10-28 |
| Low-dose Buprenorphine Initiation for Opioid Use Disorder buprenorphine-naloxone - Opioid Use Disorder | Phase 4 | Recruiting | Montefiore Medical Center | 70 | 2024-11-11 | 2026-07-21 |
| Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) DOVATO - HIV-1-infection, Opioid Use Disorder | Phase 4 | Not yet recruiting | Saskatchewan Health Authority - Regina Area | 40 | 2024-09-30 | 2024-08-30 |
| Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity Naproxen, Acetaminophen, oxycodone - Opioid Abuse (Disorder), Opioid Analgesia | Phase 4 | Enrolling by invitation | AdventHealth | 300 | 2024-08-01 | 2026-10-08 |
| Blood Naloxone Levels Following Intradermal Injection in Humans intradermal naloxone, microneedle injection - Opioid Overdose | Phase 4 | Withdrawn | Johns Hopkins University | 2024-08-01 | 2024-11-01 | |
| Low-dose Versus a High-dose Sublingual Buprenorphine Induction buprenorphine/naloxone - Opioid Use Disorder | Phase 4 | Active not recruiting | Friends Research Institute, Inc. | 40 | 2024-06-20 | 2025-08-12 |
| Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment. Methadone, Buprenorphine (BUP) - Opioid Use Disorder | Phase 4 | Recruiting | Yale University | 600 | 2024-06-04 | 2026-09-14 |
Showing 20 of 129. Sign in to see all of them.
Opioid-Related Disorders (109) · Substance-Related Disorders (18) · Opioid-Induced Constipation (10) · Opiate Overdose (8) · Pain (8) · Pain, Postoperative (8) · Chronic Pain (7) · Acquired Immunodeficiency Syndrome (6) · HIV Infections (6) · Heroin Dependence (6) · Behavior, Addictive (5) · Agnosia (4) · Hepatitis C, Chronic (4) · Emergencies (3) · Hepatitis C (3)
Chemically-Induced Disorders (129) · Mental Disorders (128) · Substance-Related Disorders (111) · Pathological Conditions, Signs and Symptoms (43) · Signs and Symptoms (36) · Neurologic Manifestations (30) · Pain (20) · Infections (17) · Pathologic Processes (15) · Blood-Borne Infections (14) · Communicable Diseases (14) · RNA Virus Infections (14) · Virus Diseases (14) · Immune System Diseases (12)
Buprenorphine (32) · Buprenorphine, Naloxone Drug Combination (32) · Naloxone (11) · Sublocade (11) · Methadone (10) · Oxycodone (9) · vivitrol (9) · Acetaminophen (4) · Fentanyl (4) · Naltrexone (4) · sofosbuvir-velpatasvir drug combination (4) · Morphine (3) · methylnaltrexone (3) · Dosage Forms (2) · Gabapentin (2)
Yale University (9) · Indivior Inc. (7) · NYU Langone Health (7) · State University of New York at Buffalo (4) · University of Alabama at Birmingham (4) · Bausch Health Americas, Inc. (3) · Pouya Azar (3) · University of Pennsylvania (3) · Albert Einstein College of Medicine (2) · Brigham and Women's Hospital (2) · Duke University (2) · Friends Research Institute, Inc. (2) · Massachusetts General Hospital (2) · Montefiore Medical Center (2) · National Institute on Drug Abuse (NIDA) (2)
United States (88) · Canada (13) · Belgium (3) · France (3) · Norway (3) · Sweden (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Germany (2) · Italy (2) · Mexico (2) · Netherlands (2) · Spain (2) · Chile (1)
Richard D Blondell, MD (3) · Aurora Quaye, MD (2) · David A. Fiellin, MD (2) · David Farabee, PhD (2) · David Fiellin, MD (2) · Enoch Bortey (2) · Li Li, MD;PhD (2) · Pouya Azar, MD (2) · Ruth Finkelstein, ScD (2) · Aaron Fox, MD (1) · Adeeba Kamarulzaman, M.D. (1) · Alexander Wong, MD (1) · Allison G Robertson, PhD, MPH (1) · Amir Kachooei, MD PhD (1) · Amr Alsabbagh, DDS (1)
PMID 36063082, PMID 37936553, PMID 40342086, PMID 12738348, PMID 12954743, PMID 14581110, PMID 14739871, PMID 15876901, PMID 15983467, PMID 16401957, PMID 16963828, PMID 17107609, PMID 17955081, PMID 18559110, PMID 18721170, PMID 18924451, PMID 20959867, PMID 21270789, PMID 21317588, PMID 21317589, PMID 21317590, PMID 21317591, PMID 21317592, PMID 21317595, PMID 21317596, PMID 21317597, PMID 21317598, PMID 21317600, PMID 21317602, PMID 21749526, PMID 21965050, PMID 23260506, PMID 23292683, PMID 23480249, PMID 23531704, PMID 23617867, PMID 23884073, PMID 24883055, PMID 24896818, PMID 24904217, PMID 25022635, PMID 25164154, PMID 25330017, PMID 25569005, PMID 25802051, PMID 26582720, PMID 27178765, PMID 27486340, PMID 27521809, PMID 27573565
1RM1DA055437-01 (1), 2017 (1), 5UG1DA015831-21 (1), I01CX002902 (1), K23AA015616 (1), K23DA055695 (1), K23DA055933 (1), K23DA057387 (1), K23DA060329 (1), P50DA009260 (1), R01DA019511 (1), R01DA020576 (1), R01DA025943 (1), R01DA030351 (1), R01DA032552 (1)